News

Twain Capital Partners Expands Financing with C-PACE Initiative

Twain Capital Partners Expands Financing with C-PACE Initiative

Twain Capital Partners Launches Innovative C-PACE Financing

Twain Capital Partners is embarking on an exciting journey in the world of financing by launching its Commercial Property Assessed Clean Energy (C-PACE) financing business. This move marks a significant expansion of Twain’s existing nationwide bridge finance operations, enabling them to cater to larger transactions that demand more complex capital solutions.

Leadership Guiding the Expansion

The expansion of Twain’s C-PACE financing initiative will be spearheaded by industry veterans Andy Meyer and Brennen Brown. These seasoned professionals bring a wealth of experience in the C-PACE landscape. Their leadership is expected to propel Twain to meet and exceed market demands effectively.

A Comprehensive Offering in Financing

Twain's new C-PACE financing options are designed to enhance their portfolio of debt offerings, which currently includes land and predevelopment bridge loans alongside USDA loans. This wide array of financial products positions Twain to effectively serve a diverse range of client needs in the commercial real estate sector.

Proven Expertise in the C-PACE Industry

The leadership team at Twain is not new to the C-PACE sector. With a collective track record of over $2 billion in C-PACE financing and more than $10 billion in commercial real estate debt and equity transactions, the team has established a reputation for excellence. Their past successes include launching two notable C-PACE finance businesses that are recognized leaders in the industry today.

Meeting Market Needs with Flexibility

In a recent statement, Andy Meyer, who serves as the Managing Partner, emphasized the need for flexible capital solutions for larger transactions. He noted that the average size of C-PACE transactions has significantly increased in recent years. This trend underscores Twain’s strategic positioning to deliver high-quality execution across various stages, from origination to loan servicing.

Adapting in a Changing Market

The C-PACE lending market is undergoing significant changes, with many lenders being consolidated into larger national asset management firms. Despite this trend, Twain Capital Partners stands out by maintaining its independence. By leveraging its robust relationships with institutional investors and insurance companies, Twain is uniquely positioned to offer adaptable and efficient capital solutions to borrowers.

Focused Financing Solutions

Twain's C-PACE financing platform is committed to providing long-term, fixed-rate financing specifically for projects related to new construction, renovations, and recently completed commercial real estate developments. The firm primarily focuses on C-PACE loans exceeding $20 million, with the capability to finance transactions ranging between $10 million and $250 million.

Continued Commitment to Diverse Offerings

In conjunction with the launch of its C-PACE financing, Twain Capital Partners will continue to offer USDA loans of up to $25 million and predevelopment bridge loans nationwide. This dual focus allows the firm to support clients at different stages of their projects while fostering growth in the commercial real estate sector.

About Twain Capital Partners

Twain Capital Partners operates as a structured finance business with dual headquarters in St. Louis, Missouri, and Salt Lake City, Utah. The firm boasts over $6 billion in assets under management, reflecting its commitment to financing commercial real estate across various development phases, including land acquisition, predevelopment, construction, and bridge financing.

Frequently Asked Questions

What is C-PACE financing?

C-PACE financing is a mechanism that allows commercial property owners to finance energy-efficient upgrades and renovations through property taxes.

Who leads the C-PACE financing initiative at Twain Capital Partners?

The initiative is led by Andy Meyer and Brennen Brown, both seasoned veterans in the C-PACE industry.

What types of loans does Twain Capital Partners offer?

Twain offers a variety of loans including C-PACE financing, USDA loans, and predevelopment bridge loans, catering to a diverse client base.

What is Twain's focus in C-PACE financing?

Twain focuses on C-PACE loans larger than $20 million, supporting significant commercial development projects.

Where are Twain Capital Partners' headquarters located?

Twain has headquarters in St. Louis, Missouri, and Salt Lake City, Utah.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Innovative Partnership Between Philips and Masimo Enhances Care

Updated Category News Views 184

New Collaboration Between Philips and Masimo In a significant development in the healthcare technology sector, Royal Philips and Masimo have announced an exciting renewal of their collaboration. This renewed partnership reflects the ongoing commitment of both companies towards innovation and improving the experiences of patients and healthcare providers alike. Advancing...

Continue Reading
Exploring Cava Group's Recent Bullish Options Activity

Updated Category News Views 102

Cava Group's Unusual Options Activity Overview Investors looking to capitalize on market trends have adopted a bullish outlook on Cava Group (CAVA). This significant move is invaluable information for retail traders. Today, we observed noteworthy activity in the options market which has been reported on various trading platforms. Such trades suggest that knowledgeable...

Continue Reading
MDU Resources Group Declares Consistent Quarterly Dividend

Updated Category News Views 139

MDU Resources Announces Quarterly Dividend Update Today, MDU Resources Group, Inc. (NYSE: MDU) has declared a quarterly dividend of 13 cents per share on its common stock, continuing its commitment to return value to its shareholders. This dividend remains unchanged from the previous quarter, reflecting the company’s stable financial position and its confidence in...

Continue Reading
JCDecaux's Q3 2024 Review: Strong Digital Growth & Future Prospects

Updated Category News Views 140

JCDecaux's Q3 2024 Business Insights On November 7, JCDecaux SE (Euronext Paris: DEC), recognized as the leading outdoor advertising firm globally, released its comprehensive report for Q3 2024, highlighting developments up to September 30, 2024. Year-Over-Year Performance During this quarter, JCDecaux reported a remarkable revenue increase of 10.9%, reaching a total of...

Continue Reading
Zealand Pharma Strengthens Presence with Roche Collaboration

Updated Category News Views 178

Exciting Collaboration Between Zealand Pharma and Roche Zealand Pharma A/S has reached a significant milestone by finalizing its collaboration and license agreement with Roche, a move widely anticipated in the biotechnology sector. The partnership marks a turning point in Zealand Pharma's mission to be a leader in innovative peptide-based therapies, especially in the...

Continue Reading